WO2003021229A3 - Diagnostic and prognostic tests - Google Patents

Diagnostic and prognostic tests Download PDF

Info

Publication number
WO2003021229A3
WO2003021229A3 PCT/US2002/028203 US0228203W WO03021229A3 WO 2003021229 A3 WO2003021229 A3 WO 2003021229A3 US 0228203 W US0228203 W US 0228203W WO 03021229 A3 WO03021229 A3 WO 03021229A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
tissue samples
sets
diagnostic
malignant
Prior art date
Application number
PCT/US2002/028203
Other languages
French (fr)
Other versions
WO2003021229A2 (en
Inventor
Gavin J Gordon
Roderick V Jensen
Steven R Gullans
Raphael Bueno
Original Assignee
Brigham & Womens Hospital
Wesleyan University
Gavin J Gordon
Roderick V Jensen
Steven R Gullans
Raphael Bueno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital, Wesleyan University, Gavin J Gordon, Roderick V Jensen, Steven R Gullans, Raphael Bueno filed Critical Brigham & Womens Hospital
Priority to AU2002324881A priority Critical patent/AU2002324881A1/en
Priority claimed from US10/236,031 external-priority patent/US7622260B2/en
Publication of WO2003021229A2 publication Critical patent/WO2003021229A2/en
Publication of WO2003021229A3 publication Critical patent/WO2003021229A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from tissue samples, such as cancer tissue samples. The invention also provides sets of genes that are expressed differentially in malignant pleural mesothelioma. These sets of genes can be used to discriminate between normal and malignant tissues, and between classes of malignant tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression/regression also are provided.
PCT/US2002/028203 2001-09-05 2002-09-05 Diagnostic and prognostic tests WO2003021229A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002324881A AU2002324881A1 (en) 2001-09-05 2002-09-05 Diagnostic and prognostic tests

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31738901P 2001-09-05 2001-09-05
US60/317,389 2001-09-05
US10/236,031 2002-08-30
US10/236,031 US7622260B2 (en) 2001-09-05 2002-09-05 Diagnostic and prognostic tests

Publications (2)

Publication Number Publication Date
WO2003021229A2 WO2003021229A2 (en) 2003-03-13
WO2003021229A3 true WO2003021229A3 (en) 2004-11-25

Family

ID=26929397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/028203 WO2003021229A2 (en) 2001-09-05 2002-09-05 Diagnostic and prognostic tests

Country Status (2)

Country Link
AU (1) AU2002324881A1 (en)
WO (1) WO2003021229A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
EP1644522A2 (en) * 2003-07-02 2006-04-12 Novartis AG Genes regulated in ovarian cancer as prognostic and therapeutic targets
WO2005015236A2 (en) * 2003-07-18 2005-02-17 Roche Diagnostics Gmbh A method for predicting the progression of adenocarcinoma
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
WO2005024043A2 (en) 2003-09-03 2005-03-17 Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
US20110152115A1 (en) 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
US8321137B2 (en) 2003-09-29 2012-11-27 Pathwork Diagnostics, Inc. Knowledge-based storage of diagnostic models
KR20060120063A (en) 2003-09-29 2006-11-24 패스워크 인포메틱스 아이엔씨 Systems and methods for detecting biological features
EP2053409A1 (en) * 2003-11-20 2009-04-29 F. Hoffmann-La Roche Ag Specific markers for metabolic syndrome
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
EP2471957A1 (en) * 2007-02-21 2012-07-04 Oslo Universitetssykehus HF New markers for cancer
US20110195064A1 (en) 2008-06-06 2011-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Survival predictor for diffuse large b cell lymphoma
WO2015161792A1 (en) * 2014-04-22 2015-10-29 Shanghai Kexin Biotech Co., Ltd. Method and biomarker for detecting cancer
CN104368012B (en) * 2014-08-20 2019-03-22 中国人民解放军第三〇七医院 The purposes and its related drugs of people's RPL34 gene
CN107312846A (en) * 2017-07-12 2017-11-03 北京赛尔维康生物医学科技有限公司 Application of the CAPG and PTGIS genes in scoliosis detection kit is prepared
CN111912987B (en) * 2020-08-25 2023-07-21 北京信诺卫康科技有限公司 FGF18 and HE4 combined used as early ovarian cancer biomarker and kit

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840484A (en) * 1992-07-17 1998-11-24 Incyte Pharmaceuticals, Inc. Comparative gene transcript analysis
US6040138A (en) * 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
WO2000055633A2 (en) * 1999-03-15 2000-09-21 Eos Biotechnology, Inc. Methods of screening for colorectal cancer modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840484A (en) * 1992-07-17 1998-11-24 Incyte Pharmaceuticals, Inc. Comparative gene transcript analysis
US6040138A (en) * 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
WO2000055633A2 (en) * 1999-03-15 2000-09-21 Eos Biotechnology, Inc. Methods of screening for colorectal cancer modulators

Also Published As

Publication number Publication date
WO2003021229A2 (en) 2003-03-13
AU2002324881A1 (en) 2003-03-18
AU2002324881A8 (en) 2003-03-18

Similar Documents

Publication Publication Date Title
WO2008021115A3 (en) Diagnostic tests using gene expression ratios
WO2003021229A3 (en) Diagnostic and prognostic tests
Salami et al. Transcriptomic heterogeneity in multifocal prostate cancer
Bolivar et al. Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients
Misawa et al. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer
WO2002009573A3 (en) Prognostic classification of endometrial cancer
WO2002010436A3 (en) Prognostic classification of breast cancer
Kristiansen Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer
Suehara et al. Proteomic signatures corresponding to histological classification and grading of soft‐tissue sarcomas
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
WO2006089233A3 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
Lee et al. Basal-like breast cancer displays distinct patterns of promoter methylation
US11286531B2 (en) Assaying ovarian cyst fluid
Wang et al. Gene expression profiling for diagnosis of triple-negative breast cancer: a multicenter, retrospective cohort study
CN107326065B (en) Screening method and application of gene marker
US9976187B2 (en) Methylation biomarkers for prostate cancer
WO2006038089A3 (en) Method for identification of neoplastic transformation with particular reference to prostate cancer
WO2005103719A3 (en) Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies
JP2015523569A5 (en)
EP1980629A3 (en) Identification of an erbb2 gene expression signature in breast cancers
Demidenko et al. Decreased expression of MT1E is a potential biomarker of prostate cancer progression
Lakhotia et al. Circulating tumour DNA in B‐cell lymphomas: current state and future prospects
Mansouri et al. Targeting of BUB1b gene expression in sentinel lymph node biopsies of invasive breast cancer in Iranian female patients
Gross-Goupil et al. Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI
Bai et al. Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP